AJI-214, with the CAS number 1395886-20-0, is a chemical compound that has been studied primarily for its potential therapeutic applications. It is classified as a selective antagonist of the cannabinoid receptor type 1 (CB1), which plays a significant role in the endocannabinoid system, influencing various physiological processes such as appetite, pain sensation, and mood regulation. The compound's structure typically includes functional groups that facilitate its interaction with the CB1 receptor, making it a subject of interest in research related to obesity and metabolic disorders. AJI-214 has been investigated for its ability to modulate the effects of cannabinoids, potentially offering a means to mitigate the psychoactive effects associated with cannabis while retaining therapeutic benefits. As with many experimental compounds, further studies are necessary to fully understand its pharmacokinetics, safety profile, and efficacy in clinical settings.

AJI-214

1395886-20-0: AJI-214, with the CAS number 1395886-20-0, is a chemical compound that has been studied primarily for its potential therapeutic applications. It is classified as a selective antagonist of the cannabinoid receptor type 1 (CB1), which plays a significant role in the endocannabinoid system, influencing various physiological processes such as appetite, pain sensation, and mood regulation. The compound's structure typically includes functional groups that facilitate its interaction with the CB1 receptor, making it a subject of interest in research related to obesity and metabolic disorders. AJI-214 has been investigated for its ability to modulate the effects of cannabinoids, potentially offering a means to mitigate the psychoactive effects associated with cannabis while retaining therapeutic benefits. As with many experimental compounds, further studies are necessary to fully understand its pharmacokinetics, safety profile, and efficacy in clinical settings.

AJI-214 functions as a dual-target inhibitor that specifically blocks Aurora kinase A and JAK2. By directly inhibiting Aurora kinase A, AJI-214 prevents mitotic progression and cell polarity in T cells while concurrently suppressing JAK2 activation to reduce STAT3 phosphorylation. This inhibition decreases the differentiation of TH1 and TH17 cells. AJI-214 is utilized in research focused on the modulation of immune responses and the prevention of graft-versus-host disease (GVHD).

CAS 1395886-20-0

AJI-214

AJI-214

Ref: TM-T200387